Berberis vulgaris alleviates Levodopa-induced dyskinesia in male mice

Open access


Introduction: Parkinson’s disease is a chronic debilitating disease and many patients use Levodopa as a major treatment. However, this drug in long-term use causes a serious condition that is known as Levodopa-induced dyskinesia (LID). Berberis vulgaris (BV) has been known to be a good potential medication for neurologic diseases such as movement disorders. The aim of this study is to investigate the usefulness of BV for LID in mice.

Material and methods: In this study, 48 adult male mice were randomly divided into six groups: 1) saline group, 2) MPTP + LID, 3) MPTP + LID + BV (5 mg/kg), 4) MPTP + LID + BV (10 mg/kg), 5) MPTP + LID + BV (20 mg/kg). MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (30 mg/kg/day/i.p.) was used to induce Parkinson’s disease and Levodopa (50 mg/kg/day/i.p.) was used to induce LID. After induction of LID, mice received intraperitoneally (i.p.) different dosages of BV for 25 days. To investigate movement disorder improvement (dyskinesia), AIMS (Abnormal Involuntary Movement Scale) and cylinder tests were used.

Results: Mice that received BV at dosages of 10 and 20 mg/kg/day showed improvement in AIMS and the cylinder test.

Conclusion: BV is a useful drug for treating LID. So, parkinsonian disease patients may get a beneficial effect after treatment with BV for LID.

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56(1):33-9.

2. Fisone G, Bezard E. Molecular mechanisms of L-DOPA-induced dyskinesia. Int Rev Neurobiol 2011; 98:95-122. doi:

3. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Dis 2010; 25(15):2649-53. doi:

4. Luginger E, Wenning G, Bösch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement Dis 2000; 15(5):873-8.

5. Calixto J. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian J Med Biol Res 2000; 33(2):179-89.

6. Rahimi-Madiseh M, Lorigoini Z, Zamani-Gharaghoshi H, Rafieian-Kopaei M. Berberis vulgaris: specifications and traditional uses. Iran J Basic Med Sci 2017; 20(5):569-87. doi:

7. Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tiss Res 2004; 318(1):215-24. doi:

8. Lee CS, Cenci MA, Schulzer M, Björklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 2000; 123(7):1365-79.

9. Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Berger SP. MK-801 inhibits LDOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism. Neuropharmacology 2010; 58(7):1002-8. doi:

10. Ardestani SB, Sahari MA, Barzegar M, Abbasi S. Some physicochemical properties of Iranian native barberry fruits (abi and poloei): Berberis integerrima and Berberis vulgaris. J Food Pharm Sci 2013;1(3). doi:

11. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Persp 2001; 109(Suppl 1):69.

12. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22(8):999-1012. doi:

13. El-Wahab AEA, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complem Alt Med 2013; 13(1):218.

14. Jiang W, Li S, Li X. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci 2015; 58(6):564-9.

15. Ahmed T, Abdollahi M, Daglia M, Nabavi SF, Nabavi SM. Berberine and neurodegeneration: A review of literature. Pharmacol Rep 2015; 67(5):970-9. doi:

16. Kim M, Cho K-H, Shin M-S, Lee J-M, Cho H-S, Kim C-J, et al. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson’s disease. Intern J Mol Med 2014; 33(4):870-8. doi:

17. Salar F, Ziai S, Nasri S, Roghani M, Kamalinejad M. Neuroprotective effect of aqueous extract of Berberis vulgaris L. in a model of Parkinson’s disease in rat. J Med Plants 2010; 9(36):24-216.

18. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007; 83(980):384-8. doi:

19. Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, et al. Dose-dependent AMPK-dependent and independent mechanisms of berberine and metformin inhibition of mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer cells. PloS ONE 2014; 9(12):e114573. doi:

20. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem 2010; 111(6):1426-36. doi:

21. Rad SZK, Rameshrad M, Hosseinzadeh H. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review. Iran J Basic Med Sci 2017; 20(5):516. doi:

22. Liu C-S, Zheng Y-R, Zhang Y-F, Long X-Y. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 2016; 109:274-82. doi:

23. Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsych Dis Treat 2013; 9:1605. doi:

Herba Polonica

From Botanical to Medical Research

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 68 68 18
PDF Downloads 62 62 15